Research programme: membrane protein inhibitors - Daiichi Sankyo/Essential Therapeutics

Drug Profile

Research programme: membrane protein inhibitors - Daiichi Sankyo/Essential Therapeutics

Alternative Names: Efflux pump inhibitors research programme - Daiichi/Essential Therapeutics; MC 04112; MC 278537

Latest Information Update: 25 Aug 2006

Price : $50

At a glance

  • Originator Daiichi Sankyo Company; Essential Therapeutics [CEASED]
  • Developer Daiichi Sankyo Company
  • Class
  • Mechanism of Action Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Pseudomonal infections

Most Recent Events

  • 25 Aug 2006 Discontinued - Preclinical for Pseudomonal infections in Japan (unspecified route)
  • 03 Apr 2006 Daiichi Pharmaceutical has merged with Sankyo to form Daiichi Sankyo Inc
  • 04 Oct 2004 Essential Therapeutics has closed down
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top